| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Angiotensin-converting enzyme (ACE)
Matrix metalloproteinase-9 (MMP-9) [1] |
|---|---|
| ln Vitro |
Matrix metalloproteinase (MMP) plays a critical role in the development of ventricular remodeling after acute myocardial infarction (AMI). Imidapril, an angiotensin-converting enzyme inhibitor, has been shown to inhibit MMP activity. We investigated whether imidapril inhibits plasma MMP activities and attenuates ventricular remodeling in patients with AMI in comparison with enalapril. We enrolled 70 patients with AMI. All patients underwent primary percutaneous coronary intervention and were randomly assigned either to imidapril (n = 35) or to enalapril (n = 35) treatment. Left ventriculography was performed in acute (day 14) and chronic (6 months) phases, and plasma MMP-2 and MMP-9 activities were measured by zymography. Any changes in left ventricular end-diastolic volume index and ejection fraction from acute to chronic phases did not differ between the 2 groups. The plasma MMP-2 and MMP-9 activities at day 14 were both significantly decreased compared with those at day 1 in both groups (all P < 0.05). At 6 months, MMP-9 activity still remained decreased in both groups (P < 0.05 vs. day 1). Overall, there were no differences between the 2 groups both in plasma MMP-2 and MMP-9 activities. These results demonstrate that imidapril exerts inhibitory effects on plasma MMP activities and attenuates left ventricular remodeling in patients with AMI similar to enalapril.[1]
|
| ln Vivo |
In patients with acute myocardial infarction (AMI) treated with Imidapril HCl (TA-6366) (2.5-10 mg/day, median 5 mg/day) starting after primary percutaneous coronary intervention, plasma MMP-2 and MMP-9 activities at day 14 were significantly decreased compared to day 1 (both P<0.05). At 6 months, MMP-9 activity remained decreased (P<0.05 vs. day 1). [1]
Left ventriculography showed no significant differences in changes of left ventricular end-diastolic volume index (LVEDVI), end-systolic volume index (LVESVI), and ejection fraction (LVEF) from acute (day 14) to chronic (6 months) phases between imidapril and enalapril groups, indicating that Imidapril HCl (TA-6366) attenuates left ventricular remodeling similar to enalapril. Effect sizes were small: d=0.01 (95% CI, -0.52 to 0.54) for LVEDVI change; d=0.19 (95% CI, -0.34 to 0.72) for LVESVI change; d=0.12 (95% CI, -0.41 to 0.65) for LVEF change. [1] Plasma brain natriuretic peptide (BNP) levels at the chronic phase were not different between imidapril and enalapril groups (75±88 vs. 92±229 pg/mL, P=not significant). [1] |
| Enzyme Assay |
Plasma samples were collected at day 1, day 14, and 6 months after AMI onset. Gelatin zymography was performed to assess MMP-2 and MMP-9 activities. Briefly, 3 μL of plasma sample was diluted into zymography sample buffer. Samples and MMP-2 standard were loaded into wells of 10% gelatin gel and electrophoresed. The gel was incubated for 1 hour at room temperature in renaturing buffer (2.5% Triton X-100), then replaced with development buffer (50 mM Tris, pH 7.5, 200 mM NaCl, 5 mM CaCl2, 1 μM ZnCl2, 0.02% Brij-35) and incubated at 37°C for 18 hours. The gel was stained with 0.5% Coomassie Blue G-250 in 30% methanol and 10% acetic acid for 3 hours, then destained. Gel was digitized and analyzed using NIH Image J software. MMP-2 and MMP-9 activities were expressed as ratios to the MMP-2 standard. [1]
|
| ADME/Pharmacokinetics |
Imidapril HCl (TA-6366) is a long-acting ACEI that is rapidly converted to its active metabolite imidaprilat in the liver. [1]
|
| References |
J Cardiovasc Pharmacol.2014 Jun;63(6):528-32.
|
| Additional Infomation |
Midapril hydrochloride is a dipeptide. Midapril hydrochloride is the hydrochloride salt of midapril, an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive effects. As a prodrug, midapril is hydrolyzed in the liver to its active form, midaprilat. Midaprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstriction of angiotensin II, leading to vasodilation. Midaprilat also reduces adrenal cortex aldosterone secretion for angiotensin II, thereby increasing sodium excretion and consequently increasing water excretion.
Imidapril HCl (TA-6366) is used for preventing left ventricular remodeling in patients with acute myocardial infarction (AMI). Its mechanism involves inhibition of angiotensin-converting enzyme (ACE) and matrix metalloproteinase (MMP-2 and MMP-9) activities. It may directly bind to the MMP-9 active site and also regulate gene expression of MMP-9 and inflammatory molecules such as TNF-α and MCP-1. [1] |
| Molecular Formula |
C20H27N3O6.HCL
|
|
|---|---|---|
| Molecular Weight |
441.91
|
|
| Exact Mass |
441.166
|
|
| CAS # |
89396-94-1
|
|
| Related CAS # |
Imidapril;89371-37-9;Imidapril-d3 hydrochloride;1356017-30-5
|
|
| PubChem CID |
5485193
|
|
| Appearance |
White to off-white solid powder
|
|
| Boiling Point |
577ºC at 760 mmHg
|
|
| Melting Point |
38-42ºC
|
|
| LogP |
1.142
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
7
|
|
| Rotatable Bond Count |
10
|
|
| Heavy Atom Count |
30
|
|
| Complexity |
619
|
|
| Defined Atom Stereocenter Count |
3
|
|
| SMILES |
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O.Cl
|
|
| InChi Key |
LSLQGMMMRMDXHN-GEUPQXMHSA-N
|
|
| InChi Code |
InChI=1S/C20H27N3O6.ClH/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28;/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26);1H/t13-,15-,16-;/m0./s1
|
|
| Chemical Name |
(4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid;hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 40 mg/mL (90.52 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2629 mL | 11.3145 mL | 22.6290 mL | |
| 5 mM | 0.4526 mL | 2.2629 mL | 4.5258 mL | |
| 10 mM | 0.2263 mL | 1.1315 mL | 2.2629 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA